EP0153955A1 - Liposome delivery method for decreasing the toxicity of an antitumor drug - Google Patents

Liposome delivery method for decreasing the toxicity of an antitumor drug

Info

Publication number
EP0153955A1
EP0153955A1 EP19840903412 EP84903412A EP0153955A1 EP 0153955 A1 EP0153955 A1 EP 0153955A1 EP 19840903412 EP19840903412 EP 19840903412 EP 84903412 A EP84903412 A EP 84903412A EP 0153955 A1 EP0153955 A1 EP 0153955A1
Authority
EP
European Patent Office
Prior art keywords
drug
alpha
tocopherol
liposomes
toxicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19840903412
Other languages
German (de)
French (fr)
Inventor
Eric Mayhew
Youcef M. Rustum
Fred C. Olson
David E. Maslow
Francis C. Szoka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of EP0153955A1 publication Critical patent/EP0153955A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids

Definitions

  • the method comprises trapping the drug and a drug-protective compound, at a selected ratio, in the same lipid bilayer vesicles.
  • the drug-protective compound is one which itself decreases the toxicity of the drug when both compounds are administered in free form.
  • the anti-tumor drug is AM
  • the drug-protective compound is alpha-tocopherol
  • the toxicity of AM when encapsulated in liposomes containing alpha-tocopherol is decreased more than about 60% over that of AM entrapped in vesicles containing no alpha-tocopherol. It is one object of the invention, therefore, to provide a novel method for reducing the toxicity of drugs.
  • a more particular object of the invention is to provide a method for reducing the toxicity of an anti-tumor drug, such as AM. by including the drug in liposomes also containing a drug-protective compound, such as alpha-tocopherol.
  • Still another object of the invention is to provide such a method which is applicable to a wide range of drugs and drug-protective compounds, both soluble and lipophilic.
  • a further object of the invention is to provide a therapeutic agent comprising liposomes containing an entrapped anti-tumor drug, such as AM, and a coentrapped drug-protective compound. 5
  • Multilamellar liposomes were made by first mixing 60 ⁇ oles of a 1:4:4 molar ratio mixture of phosphatidylglycerol; phophatidylcholine and cholesterol (in chloroform) with 1.5 mg AM (in methanol) and 0.6
  • the therapeutic effects of AM were tested using DBA 2J mice injected intraperitoneally with 10 L1210 leukemia cells.
  • the animals were treated one day later by intravenous injection of AM, either in the form of free AM, liposomes entrapping AM only (AM/liposomes). or liposomes entrapping both AM and alpha-tocopherol (AM-aT/liposomes) .
  • the dosages of AM administered expressed in milligrams AM per kilogram animal body weight, are given at the left in Table I below.
  • the day of death of the animals was recorded, and the mean survival time of each group was calculated. Each group contained from between 6 and 10 mice. The mean survival time and calculated standard deviations are shown at the three columns at the right in Table I.
  • AM-aT/liposomes in doses of 2, 5, 10, 15, 20, 25, 30. 50, 75, 100 mg AM per kg animal body weight.
  • the data are expressed in terms of LD ⁇ o , i.e., the dosage (in mg drug per kilogram of animal body weight) which produces death in half the animals receiving the drug.
  • the upper row in Table II gives the D 5 _ data for mice dying within 14 days after drug administration (acute), the lower row, for mice dying between 50 and 120 days after drug administration (chronic).
  • the number of mice available for determination of chronic toxicity (survival of acute toxicity) varied from between about 2 and 10 mice per group.
  • Mean LD 5 _ (mg/kg) +.S.D. free AM AM/liposomes AM-aT/liposomes acute 20 +5 45 ⁇ 5 >75 chronic 12 +5 30 +5 50
  • drug-protective liposomes described herein had an alpha-tocopherol to total lipid ratio of about 1:100.
  • the ratio of alpha-tocopherol to total liposome lipids can be made much greater, preferably in the molar ratio range of 1:20 to 1:5, i.e.. between about 5 and 20 mole percent alpha-tocopherol.
  • a preferred therapeutic agent of the invention comprises liposomes containing phospholipid.
  • cholesterol, alpha-tocopherol succinate and AM at molar percentages of between about 30% and 70%, 20% and 50%, 5% and 20% and 0.2% and 15%, respectively.
  • the data supports the concept of using liposomes to carry more than one agent simultaneously, where one of the agents is a drug and the other agent is either a drug-protective compound, such as disclosed herein, or a drug-potentiating compound which promotes the action of the drug at the site of drug delivery.
  • examples of other drug-protective compounds which have been shown to reduce anthracycline cardiac toxicity when administered in free form, include hydroxybutylated toluene, N-acetylcysteine (reference 15) and niacin and isocitrate (reference 16). In practicing the method of the present invention, these compounds would be coentrapped, for example, at encapsulated concentrations of between about 5-100 mg/ml in anthracycline-containing liposomes. to produce an enhanced reduction in drug toxicity.
  • Compounds that potentiate anthracycline activity include agents that block calcium uptake, such as verapamil (reference 17). compounds that interfere with calcium mobilization from an intracellular store, such as 8-(N,N-diethylamino)-octyl-3. 4,5-trimethoxy- benzoate (TMB-8) (reference 18), or compounds that interfere with calcium binding to the protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Procédé visant à diminuer la toxicité d'un médicament antitumoral. Le médicament est emprisonné dans des liposomes contenant également un composé protecteur contre les effets secondaires du médicament.A method of decreasing the toxicity of an anti-tumor drug. The drug is trapped in liposomes also containing a protective compound against the side effects of the drug.

Description

Liposome Delivery Method for Decreasing the Toxicity of an Antitumor Drug
Background and Summary
The following references are referred to by corresponding number in this application: 1. Forssen, E. A. and Tokes, Z. A. In vitro and in vivo studies with adriamycin liposomes. Biochem Biophvs Res Comm 91:1295-1301 (1979).
2. Forssen. E. A. and Tokes, Z. A. Use of anionic liposomes for the reduction of chronic doxorubicin induced cardiotoxicity. Proc Nat Acad Sci USA 18:1873-1877 (1981).
3. Maslow, D. E., Mayhew. E., Olson, F.. and Rustum,
Y. Reduction of the inhibitory effect of Adriamycin on myocardial contraction jLn vitro by entrapment in liposomes. Proc Am Assoc Cancer Res 21:281 (1980).
4. Olson, F., Mayhew, E. , Haslow, D. , Rustum, Y. and SzoJca, F. Characterization, toxicity and therapeutic efficacy of adriamycin encaparjlated in liposomes. Eur J Cancer Clin Oncol 18(2) :167(1982) . 5. Rahman, A., essler, A., More, N. , Sikie, B.,
Rowden, G., Woolley, P. and Schein, P. S. Liposomal protection of adriamycin-induced cardiotoxicity in mice. Cancer Res 40:1532-1537 (1980). 6. Diplock, A. T., Lucy, J. A., Verrirder, M. and Zieliniewski, A. Alpha-tocopherol and the permeability to glucose and chromate of unsaturated liposomes. Febs Lett 82:341-344 (1977).
7. Fukazawa, K. , ∑keno, H. , Tokumura, A., and Tsukatani, H. Effect of alpha-tocopherol incorporation on glucose permeability and phase transition of lecithin liposomes. Chem Phys Lip 21:13-22 (1979).
8. Myers, E., McGuire, W. and Young, R. , Adriamycin: amelioration of toxicity by alpha-tocopherol. Cancer Treatment Reports 60:961-962 (1976).
9. Sonneveld, P. Effect of alpha-tocopherol on the cardiotoxicity of adriamycin in the rat. Cancer Treatment Reports 62:1033-1036 (1978).
10. Hang, Y.-M. , Madanat, F. F., Kimball, J. C. , Gleiser, C. A., Ali, M. K. , Kaufman. M. Q. and van Eyes, J. Effect of vitamin E against Adriamycin-induced toxicity in rabbits. Cancer Res 49.:1022-1027 (1980).
11. Mayhew, E. and Rustum, Y. M. Effects of liposome entrapped adriamycin (AM) against ovarian tumor
M5076 "metastatic" to the liver. Proc Am Assoc Cancer Res 23:170 (Abstract #668) (March. 1982).
12. Hunt, C. A. and Tsang, S. Alpha-tocopherol retards auto-oxidation and prolongs the shelf life of liposomes. Int J Pharmaceutics 8:101-110 (1981).
13. Konigs. A. W. T., Darren, J. and Trieling, W. B. Protection of liposomal lipids against radiation induced oxidative damage. Int J Radiat Biol
3J5:343-350 (1979). 14. Mayhew, E., Rustum, Y. M. , Szoka, F. and
Papahadjopoulos, D. Role of cholesterol in enhancing the anti-tumor activity of
OMPI fa WIPO Λ,. 1-alpha-D-Arabinofuranosylcytosine entrapped in reverse phase evaporation vesicles. Cancer Treatment Reports 63:1923-1928 (1979). 15. Doroshaw, J. H. , et al, J Clin Invest 68:1053 (1981) 516. Scheulen, M. E., et al, Proc Am Assoc Cancer Res 23:992(1983).
17. Rogan, A. M.. et al. Science 224:994 (1984).
18. Juhl, H., et al, Biochem Biophys Res Commun 106(1):210 (1982).
1019. Weiss, B.. Annals N Y Acad Sci 356:319 (1980).
Entrapment of adriamycin (AM) in lipid bilayer vesicles, or liposomes has been reported to reduce the toxicity of this drug in animals, probably by 5 cardiotoxicity reduction (references 1-5). In addition, alpha-tocopherol (vitamin Ξ), which has been reported to stabilize phospholipid membranes (references 6,7), has also been reported to reduce the cardiotoxicity of AM in animals when both compounds are administered in the free 0 form (references 8-10). A study reported by two of the inventors herein suggests that AM entrapped in liposomes containing entrapped alpha-tocopherol is more effective against tumor growth in mice than is free AM (reference 11). Studies conducted in support of the parent 5 application and reported herein, indicate that at the AM dosage where increased effectiveness of liposome- entrapped AM is observed, the increase is about the same whether or not the entrapping liposomes contain alpha-tocopherol. None of the above-mentioned studies 0 suggest that liposomes containing both entrapped AM and alpha-tocopherol have important therapeutic properties not found in liposomes containing entrapped AM only.
An important feature of the invention, therefore, is the finding that liposomes containing both AM and alpha-tocopherol are substantially less toxic than other AM formulations whose toxicity has been studied. These findings have led to an improved method for decreasing the toxicity of drugs generally. The method comprises trapping the drug and a drug-protective compound, at a selected ratio, in the same lipid bilayer vesicles. The drug-protective compound is one which itself decreases the toxicity of the drug when both compounds are administered in free form. In a specific embodiment of the invention, the anti-tumor drug is AM, the drug-protective compound is alpha-tocopherol and the toxicity of AM when encapsulated in liposomes containing alpha-tocopherol. is decreased more than about 60% over that of AM entrapped in vesicles containing no alpha-tocopherol. It is one object of the invention, therefore, to provide a novel method for reducing the toxicity of drugs.
A more particular object of the invention is to provide a method for reducing the toxicity of an anti-tumor drug, such as AM. by including the drug in liposomes also containing a drug-protective compound, such as alpha-tocopherol.
Still another object of the invention is to provide such a method which is applicable to a wide range of drugs and drug-protective compounds, both soluble and lipophilic.
A further object of the invention is to provide a therapeutic agent comprising liposomes containing an entrapped anti-tumor drug, such as AM, and a coentrapped drug-protective compound. 5 These and other objects and features of the invention will become more fully apparent from the following detailed description of the invention.
Detailed Description of the Invention Phospholipids and purified cholesterol were
10 prepared as described previously (reference 13). Multilamellar liposomes were made by first mixing 60 μ oles of a 1:4:4 molar ratio mixture of phosphatidylglycerol; phophatidylcholine and cholesterol (in chloroform) with 1.5 mg AM (in methanol) and 0.6
15 μmoles alpha-tocopherol (in chloroform). AM
(doxorυbicin) was obtained from Adria Corp. (Columbus, OH). The AM-containing lipid mixture was evaporated by a rotary evaporation at room temperature. Phosphate buffered saline free of calcium and magnesium (PBS), pH
207.4 was added (1 ml/60 μmoles lipid) at 37°C and the suspension was shaken at 37°C overnight. The heterogeneous multilamellar liposome suspension which formed was extruded through a 0.4 micron nucleopore filter under 40-80 psi nitrogen pressure at room
25 temperature and centrifuged at 130,000 x g for 1 hr at 20°C to concentrate the liposomes and to remove much of the non-entrapped AM. The liposomes were extensively dialyzed against 100-200 volumes of PBS with stirring at 37°C. The percent of AM entrapped, determined by 0 fluorescence spectrophotometry. was between about 65% and 70%. The calculated molar ratio of alpha-tocopherol to total lipids in the liposomes is about 1:100. Substantially all of the alpha-tocopherol was trapped in the liposomes. The same procedure was used to prepare liposomes entrapping AM but containing no alpha-tocopherol (by omitting alpha-tocopherol from the preparation) as described previously (4).
The therapeutic effects of AM were tested using DBA 2J mice injected intraperitoneally with 10 L1210 leukemia cells. The animals were treated one day later by intravenous injection of AM, either in the form of free AM, liposomes entrapping AM only (AM/liposomes). or liposomes entrapping both AM and alpha-tocopherol (AM-aT/liposomes) . The dosages of AM administered, expressed in milligrams AM per kilogram animal body weight, are given at the left in Table I below. The day of death of the animals was recorded, and the mean survival time of each group was calculated. Each group contained from between 6 and 10 mice. The mean survival time and calculated standard deviations are shown at the three columns at the right in Table I.
Table I dose AM Mean Survival Time (days) 1 +. S.D.
(mg/kg) free AM AM/liposomes AM- -aT/liposomes
0 7.2 +0.4 - - —
10 18.4 +1.8 16.8 +2.4 17.6 +3.0
20 12.2 +1.6 17.6 +2.0 16.8 +1.6
50 _ 13.0 +4.3 17.0 +4.0
The data in Table I show that at a dosage of 10 mg/kg, the anti-leukemic effectiveness of free AM was maintained, but not improved, by entrapment in liposomes alone or liposomes containing alpha-tocopherol. At the
20 mg/kg dosage level, the effectiveness of liposome- entrapped AM, either in the presence or absence of alpha-tocopherol was better than that of free AM at the same concentration, similar to what was reported in reference 11. However, at no AM dosage level was the effectiveness of AM entrapped in liposomes, either in the presence of absence of alpha-tocopherol, greater than the optimal, 10 mg/kg dosage level of free AM.
Similar studies were performed to determine the effect of the various AM formulations on long-term survival in mice which had been injected intra-
5 peritoneally with 10 L1210 leukemia cells. The infected animals were treated with intraperitoneal injections of AM (10 mg/kg body weight) administered either as free AM, AM encapsulated in liposomes, AM encapsulated in liposomes also containing alpha- tocopherol, or a mixed population of liposomes containing AM only and liposomes containing alpha- tocopherol only. Significantly, the only AM formulation that gave long-term survival (2 of 6 mice survived to 172 days after initial infection) was the lipoβome formulation containing conentrapped AM and alpha-tocopherol.
At least under certain therapeutic conditions, then, supplying the drug and drug-protective compound in the same liposome population produced therapeutic results which are superior to those obtained by administering the drug and drug protective compound in separate liposome populations. The results suggest that release of a drug (in this case, an anthracycline anti-tumor drug) and a drug-related compound (in this case, a drug protective compound) in the same localized liposome-target region may have important therapeutic consequences not realized heretofore. The toxicity of the three AM preparations described with respect to Table I was tested against healthy DBA 2J mice. Groups of mice (6-10 mice/group) were injected with a single iv dose of free AM, liposomes entrapping AM only (AM/liposomes), and liposomes entrapping both AM and alpha-tocopherol
(AM-aT/liposomes) in doses of 2, 5, 10, 15, 20, 25, 30. 50, 75, 100 mg AM per kg animal body weight.
In the experiment, which is reported in Table II below, it was found that the mice died at two distinct time periods after administration: within 3-14 days, and between approximately 8-12 weeks after drug administration. The data are expressed in terms of LDςo, i.e., the dosage (in mg drug per kilogram of animal body weight) which produces death in half the animals receiving the drug. The upper row in Table II gives the D5_ data for mice dying within 14 days after drug administration (acute), the lower row, for mice dying between 50 and 120 days after drug administration (chronic). The number of mice available for determination of chronic toxicity (survival of acute toxicity) varied from between about 2 and 10 mice per group.
Table II
Mean LD5_ (mg/kg) +.S.D. free AM AM/liposomes AM-aT/liposomes acute 20 +5 45 ±5 >75 chronic 12 +5 30 +5 50
The data in Table II confirm that both acute and chronic toxicity of AM are reduced more than 2-fold by encapsulating the drug in liposomes containing no alpha-tocopherol, as has been reported previously. According to an important finding of the present invention, entrapping the drug in liposomes which also contain entrapped alpha-tocopherol further reduces acute and chronic toxicity more than about 60% with respect to liposomes entrapping AM alone. It is noted that 75 mg/kg is about the highest drug dosage which could be administered with a single intravenous injection. Therefore the D5Q value for acute toxicity from AM-aT/liposomes may be somewhat higher than shown.
The results presented herein suggest that it may be possible to use a total cumulative dose of AM, after co-entrapment with alpha-tocopherol in liposomes, several times greater than that possible with the free drug. Alternatively, similar doses of the liposome-entrapped drug only could be used with reduced risk of cardiotoxicity.
Further reduction in drug toxicity may be achieved by increasing the relative amount of drug protective compound in the drug-containing liposomes. As noted above, drug-protective liposomes described herein had an alpha-tocopherol to total lipid ratio of about 1:100. Using an alpha-tocopherol succinate, the ratio of alpha-tocopherol to total liposome lipids can be made much greater, preferably in the molar ratio range of 1:20 to 1:5, i.e.. between about 5 and 20 mole percent alpha-tocopherol. A preferred therapeutic agent of the invention comprises liposomes containing phospholipid. cholesterol, alpha-tocopherol succinate and AM at molar percentages of between about 30% and 70%, 20% and 50%, 5% and 20% and 0.2% and 15%, respectively. The data supports the concept of using liposomes to carry more than one agent simultaneously, where one of the agents is a drug and the other agent is either a drug-protective compound, such as disclosed herein, or a drug-potentiating compound which promotes the action of the drug at the site of drug delivery. Examples of other drug-protective compounds, which have been shown to reduce anthracycline cardiac toxicity when administered in free form, include hydroxybutylated toluene, N-acetylcysteine (reference 15) and niacin and isocitrate (reference 16). In practicing the method of the present invention, these compounds would be coentrapped, for example, at encapsulated concentrations of between about 5-100 mg/ml in anthracycline-containing liposomes. to produce an enhanced reduction in drug toxicity.
Compounds that potentiate anthracycline activity include agents that block calcium uptake, such as verapamil (reference 17). compounds that interfere with calcium mobilization from an intracellular store, such as 8-(N,N-diethylamino)-octyl-3. 4,5-trimethoxy- benzoate (TMB-8) (reference 18), or compounds that interfere with calcium binding to the protein
OMPΓ '• WIPO $ calmodulin, such as trifluoroperazine. thioridozine. and other compounds noted in reference 19. These compounds would be included, at normal therapeutically effective doses, and/or maximum concentrations consistent with liposome membrane stability, in liposomes also formulated to contain encapsulated an anthracycline drug, and administered in a suitable manner, such as is detailed above.
While the present invention has been illustrated with respect to one particular embodiment, it will be appreciated by those skilled in the art that various changes and modificatios can be made without departing from the scope and spirit of the invention.

Claims

WHAT IS CLAIMED IS:
1. A method for decreasing the toxicity of a drug substantially below that produced when the drug alone is entrapped in lipid bilayer vesicles, or that produced when the drug and a drug-protective compound are both administered in free form, the drug-protective compound being one which itself decreases the toxicity of the drug when administered with the drug in free form, said method comprising entrapping the drug and the compound, at a selected drug-to-compound ratio, in the same lipid bilayer vesicles.
2. The method of claim 1, wherein the drug-protective compound includes an anthracycline drug.
3. The method of claim 2. wherein the drug protective compound is selected from the group consisting of alpha-tocopherol, alpha-tocopherol succinate, N-acetylcysteine, niacin, isocitrate, and β-hydroxybutylated toluene.
4. The method of claim 2. wherein the drug includes adriamycin, the drug-protective compound includes alpha-tocopherol, and the toxicity of the drug entrapped in lipid vesicles also containing alpha-tocopherol, as measured in mice, is decreased at least about 50% below the toxicity of the drug entrapped in vesicles containing no alpha-tocopherol.
5. A therapeutic agent comprising liposomes containing phospholipid, cholesterol, alpha-tocopherol
^NATIO≤^ succinate, and adriamycin at molar percentages between about 30% and 70%, 20% and 50%, 5% and 20% and 0.2% and 15%, respectively.
EP19840903412 1983-09-06 1984-09-06 Liposome delivery method for decreasing the toxicity of an antitumor drug Withdrawn EP0153955A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52989083A 1983-09-06 1983-09-06
US529890 1995-09-18

Publications (1)

Publication Number Publication Date
EP0153955A1 true EP0153955A1 (en) 1985-09-11

Family

ID=24111649

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19840903412 Withdrawn EP0153955A1 (en) 1983-09-06 1984-09-06 Liposome delivery method for decreasing the toxicity of an antitumor drug

Country Status (2)

Country Link
EP (1) EP0153955A1 (en)
WO (1) WO1985000968A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861580A (en) * 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
IE58981B1 (en) * 1985-10-15 1993-12-15 Vestar Inc Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles
US5041278A (en) * 1985-10-15 1991-08-20 The Liposome Company, Inc. Alpha tocopherol-based vesicles
JPH0617309B2 (en) * 1985-11-29 1994-03-09 株式会社ビタミン研究所 Adriamycin embedded liposome preparation
US4923854A (en) * 1986-01-22 1990-05-08 The Liposome Company, Inc. Solubilization of hydrophobic materials using lysophospholipid
US5204112A (en) * 1986-06-16 1993-04-20 The Liposome Company, Inc. Induction of asymmetry in vesicles
US5252263A (en) * 1986-06-16 1993-10-12 The Liposome Company, Inc. Induction of asymmetry in vesicles
MX9203808A (en) * 1987-03-05 1992-07-01 Liposome Co Inc HIGH DRUG CONTENT FORMULATIONS: LIPID, FROM LIPOSOMIC-ANTINEOPLASTIC AGENTS.
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US5616334A (en) * 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
JPH02502978A (en) * 1987-04-16 1990-09-20 ザ　リポソーム　カンパニー，インコーポレイテッド Method and device for continuous size reduction of liposomes
US5082664A (en) * 1987-05-22 1992-01-21 The Liposome Company, Inc. Prostaglandin-lipid formulations
US5925375A (en) * 1987-05-22 1999-07-20 The Liposome Company, Inc. Therapeutic use of multilamellar liposomal prostaglandin formulations
US5262168A (en) * 1987-05-22 1993-11-16 The Liposome Company, Inc. Prostaglandin-lipid formulations
MX9203804A (en) * 1987-10-19 1992-07-01 Liposome Co Inc PHARMACEUTICAL SYSTEMS BASED ON TOCOPHEROL.
US4981690A (en) * 1987-10-27 1991-01-01 Board Of Regents, The University Of Texas System Liposome-incorporated mepartricin
US4946683A (en) * 1987-11-18 1990-08-07 Vestar, Inc. Multiple step entrapment/loading procedure for preparing lipophilic drug-containing liposomes
WO1989006654A1 (en) * 1988-01-19 1989-07-27 Board Of Regents, The University Of Texas System Glycosides, liposomal compositions thereof, and methods for their use
US5948441A (en) * 1988-03-07 1999-09-07 The Liposome Company, Inc. Method for size separation of particles
US5049392A (en) * 1989-01-18 1991-09-17 The Liposome Company, Inc. Osmotically dependent vesicles
DE69027598T2 (en) * 1989-03-13 1996-10-31 Kenneth N Matsumura COMPOSITION TO REDUCE THE SIDE EFFECTS OF A MEDICINAL PRODUCT
DE1118326T1 (en) * 1993-05-21 2002-04-18 Liposome Co Inc Reduction of physiological counter-reactions induced by liposomes
ES2072223B1 (en) * 1993-11-25 1996-03-16 Lipotec Sa LIPOSOMES ENCAPSULATING DOXORUBICIN.
IL136343A0 (en) * 1997-12-04 2001-05-20 Yissum Res Dev Co Combined chemo-immunotherapy with liposomal drugs and cytokines
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
ES2186484B1 (en) 2000-10-10 2004-07-01 Lipotec, S.A. LIPOSOMES ENCAPSULATING ANTI-CANCER DRUGS AND USE OF THEM IN THE TREATMENT OF EVIL TUMORS.
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
KR101171045B1 (en) * 2002-12-31 2012-08-03 자이더스 비에스브이 파마 프라이빗 리미티드 Composition Comprising A Long-Circulating Non-Pegylated Liposomes and Its Manufacture
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
CA2838111C (en) 2005-12-08 2016-01-19 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US20100196455A1 (en) 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
CN108743537B (en) 2012-05-21 2021-06-11 英斯麦德公司 System for treating pulmonary infections
MX2015002842A (en) 2012-09-04 2015-08-12 Eleison Pharmaceuticals LLC Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin.
CN104884047A (en) 2012-11-29 2015-09-02 英斯梅德股份有限公司 Stabilized vancomycin formulations
MX2016014921A (en) 2014-05-15 2017-07-28 Insmed In Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections.
US10363226B2 (en) 2015-08-12 2019-07-30 North Carolina State University Platelet membrane-coated drug delivery system
US11571386B2 (en) 2018-03-30 2023-02-07 Insmed Incorporated Methods for continuous manufacture of liposomal drug products

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993754A (en) * 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
US4263428A (en) * 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IL55431A (en) * 1978-08-24 1982-07-30 Yeda Res & Dev Anthracycline type antibiotics,their preparation and pharmaceutical compositions comprising them
US4241046A (en) * 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4419348A (en) * 1981-04-27 1983-12-06 Georgetown University Anthracycline glycoside compositions, their use and preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8500968A1 *

Also Published As

Publication number Publication date
WO1985000968A1 (en) 1985-03-14

Similar Documents

Publication Publication Date Title
EP0153955A1 (en) Liposome delivery method for decreasing the toxicity of an antitumor drug
US4873088A (en) Liposome drug delivery method and composition
Cortesi et al. Formulation study for the antitumor drug camptothecin: liposomes, micellar solutions and a microemulsion
Rubas et al. Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes
US5741516A (en) Sphingosomes for enhanced drug delivery
Mayhew et al. Pharmacokinetics and antitumor activity of epirubicin encapsulated in long‐circulating liposomes incorporating a polyethylene glycol‐derivatized phospholipid
US5178876A (en) Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US4769250A (en) Antracycline antineoplastic agents encapsulated in phospholipid vesicle particles and methods for using same for tumor therapy
CA1338702C (en) High drug:lipid formulations of liposomal- antineoplastic agents
Harrington et al. Liposomes as vehicles for targeted therapy of cancer. Part 1: preclinical development
Gabizon et al. Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumour model
US4863739A (en) Liposome compositions of anthracycline derivatives
Boman et al. Encapsulation of vincristine in liposomes reduces its toxicity and improves its anti-tumor efficacy
US7029696B2 (en) Delivery and activation through liposome incorporation of diaminocyclohexane platinum(II) complexes
Lopez-Berestein et al. Prophylaxis and treatment of experimental lung metastases in mice after treatment with liposome-encapsulated 6-O-stearoyl-N-acetylmuramyl-L-α-aminobutyryl-D-isoglutamine
Chang et al. Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice
CA2508166A1 (en) Compositions and methods related to lipid:emodin formulations
Schwendener et al. Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy
HOSODA et al. Antitumor activity of doxorubicin encapsulated in poly (ethylene glycol)-coated liposomes
Sur et al. Effect of liposomal encapsulation of cis-platinum diamminodichloride in the treatment of Ehrlich ascites carcinoma
DOI et al. Therapeutic effect of reticuloendothelial system (RES)-avoiding liposomes containing a phospholipid analogue of 5-fluorouracil, dipalmitoylphosphatidylfluorouridine, in Meth A sarcoma-bearing mice
AU756109B2 (en) Methods for antitumor therapy
WO2000009071A2 (en) A novel liposomal formulation useful in treatment of cancer and other proliferation diseases
GB2143433A (en) Methotrexate ointment
NAGATA et al. Antitumor activity against human gastric cancers of sulfatide-inserted liposomes containing entrapped adriamycin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19850807

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MASLOW, DAVID, E.

Inventor name: SZOKA, FRANCIS, C.

Inventor name: RUSTUM, YOUCEF, M.

Inventor name: OLSON, FRED, C.

Inventor name: MAYHEW, ERIC